Spyre Therapeutics, Inc.

This Phase 2 trial is testing three long-acting antibodies, alone or in combination, for people with moderate-to-severe ulcerative colitis. The study will enroll 645 adults to see if these treatments can reduce inflammation and lead to remission. Participants receive the antibodi…